BHI MCEDC LOGOS

Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH, the University of Maryland MIPS program, and others.  Learn the latest about the current areas of focus for nondilutive funding resources, tips for submitting successful applications, and additional resources to support your early-stage company.  Confirmed speakers and partnering meeting participants include:

  • Henry Ahn - Program Director, National Science Foundation (NSF)
  • Lynne Stein Benzion – Director, Economic Development, Montgomery County Econ. Dev. Corp. (MCEDC)
  • Katie Bratlie - Program Director, National Science Foundation (NSF)
  • Christie Canaria, PhD - Program Director, SBIR Development Center, National Cancer Institute (NCI)
  • Judy Costello – Managing Director, Economic Development, BioHealth Innovation (BHI)
  • Stephanie Davis, PhD - Small Business Program Coordinator, NIH Nat’l Heart Lung & Blood Inst. (NHLBI)
  • Sharon Disque, Economic Development Manager, City of Gaithersburg, Maryland
  • Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
  • Jonathan Franca-Koh, PhD - Program Director, SBIR Development Center, National Cancer Inst (NCI).
  • Armineh Ghazarian - Program Analyst, NIH National Institute of Aging (NIA)
  • Colleen Gibney, SBIR Deputy Project Manager, USAMRMC (DoD)
  • Todd Haim, PhD - Chief, Office of Small Business Research, NIH National Institute of Aging (NIA)
  • Elena Koustova, PhD, MBA - Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
  • Ashwin Kulkarni, COO, miRecule; Associate, BioHealth Innovation, Inc. (BHI)
  • Carla Merritt, Senior Business Development Representative, Maryland Department of Commerce
  • JR Meyers, SBIR Project Manager, USAMRMC (DoD)
  • Alastair Monk - Program Director, National Science Foundation (NSF)
  • Deepa Narayanan - Program Director and Team Lead, NIH National Cancer Institute SBIR Development Center (NCI)
  • Rini Pek PhD - Senior Analyst, BioHealth Innovation, Inc. (BHI)
  • Erik Pierstorff - Program Director, National Science Foundation (NSF)
  • Victor Prikhodko - Senior Business Dev. Mgr., SBIR/STTR NIH National Inst. of Drug Abuse (NIDA)
  • Monique Pond, PhD - Program Director, SBIR Development Center, National Cancer Institute
  • Reema Railkar, PhD Program Manager, SBIR Development Center, National Cancer Institute
  • Saroj Regmi, PhD - Health Science Administrator, Office of Small Business Research, NIH National Institute of Aging
  • Andrea Renner - SBIR Deputy Project Manager, USAMRMC (DoD)
  • Ethel Rubin, PhD - Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
  • Anthony Saleh, PhD – CEO, miRecule
  • Ben Schrag, PhD - Program Director, National Science Foundation (NSF)
  • John Sullivan - Entrepreneur-in-Residence, BioHealth Innovation, Inc. (BHI)
  • Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (MTech), University of Maryland

Register (no fee) today!    www.tinyurl.com/2021SBIR

To see the full agenda, Click here.

BHI Logo

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI EIRs here: www.tinyurl.com/EIRfeedback.  These take place by videoconference via Zoom.  Pre-registration and forwarding of a power point deck one week before the session is required. For questions, more information, or to be added to the wait list, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Please review the available slots below and click on the button to register. Thank you!

 

NewImage

 A free, virtual Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond, presented by EAGB & BHI.

The Economic Alliance of Greater Baltimore (www.greaterbaltimore.org) and BioHealth Innovation (www.biohealthinnovation.org) have partnered to host a Forum focused on the growing Digital Health industry in the Baltimore/Washington region and beyond. The Forum is free and will be held virtually on March 25, from1 – 3:00 pm. There is no fee and all are welcomed, but you must register in order to receive the link to the event.

The Digital Health Forum features two panel discussions and a moderated conversation. Brief welcome comments by Rich Bendis and Michele Whelley, CEO of BHI and EAGB, respectively, will open the Forum.

  • PANEL ONE: The Role of Academia in Digital Health
  • PANEL TWO: Digital Health in Healthcare
  • CLOSING CONVERSATION: International Collaboration in Digital Health

Visit https://bit.ly/DigitalHealth21 to learn more and register for this FREE Event today.

Sponsored by: First National Bank, Olive, and TEDCO

 

Bendis Conference 2021

This free webinar will feature a fireside chat-style conversation with Dr. Robert Scharpf (Delfi Diagnostics) and Dr. Christie Bergerson (Exponent). Drs. Scharpf and Bergerson will discuss how machine learning and artificial intelligence are impacting biomedical engineering and the wider world of human health.

Rich Bendis (BioHealth Innovation/BioTalk podcast) will facilitate the discussion. View the speaker bios for more information.

After the main session, participants will have the opportunity to join one of three, smaller breakout sessions:

  • Meet and Greet with the Featured Speakers - Continue the conversation with Drs. Scharpf and Bergerson for an informal Q&A session about their work and the field.
  • Careers at the Intersection of Artificial Intelligence and Biotechnology - Join Rich Bendis and other industry representatives in exploring career opportunities in the emerging biotechnology, data science, and public health fields. 
  • What is Biocomputational Engineering? Learn about UMD's new bachelor's degree - Join program staff to learn about the exciting new University of Maryland degree aimed at preparing students for careers in the data science and biotechnology sector. Launching in Fall 2021 at the Universities at Shady Grove, this program is conveniently located in Rockville, MD – a biotech powerhouse just outside the nation's capital.

 

PhlowUSP

Richmond, VA., February 22, 2021 – Phlow Corp., a public benefit essential medicines solutions provider, and the United States Pharmacopeia (USP) today announced a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines. Throughout its 200-year history of setting standards for medicine quality, USP has been providing validated scientific methods used by manufacturers and regulators to determine what “good quality” looks like. The methods developed through this strategic alliance will be available for use by other domestic generics manufacturers to encourage broader adoption of Pharmaceutical Continuous Manufacturing in order to strengthen the U.S. drug supply.

USP, a global, scientific not-for-profit organization located in Rockville, Maryland, develops public standards that establish the quality expectations for medicines, collaborating with scientific experts from the academic, industry, and healthcare practitioner communities along with the U.S. FDA. The alliance will facilitate Phlow’s application of “flow” chemistry and other continuous advanced manufacturing processes to produce the crucial ingredients that enable domestic, end-to-end drug manufacturing of essential medicines that have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain.

 

Emergent Logo

Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.

It’s a critical role not taken lightly by the employees in the company’s two Baltimore-based facilities. Sean Kirk, executive vice president of Manufacturing and Technical Operations at Emergent, said the importance of the work taken on by Emergent, as well as the biopharma industry at large to battle the pandemic is not lost on him.

 

altimmune logo

Shares of Altimmune Inc. ALT were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine. The study is expected to enroll up to 180 healthy adults between the ages of 18 and 55 years old, who will receive one of three doses of the experimental vaccine. The company said it expects to share the first batch of clinical data from this trial in the second quarter of this year. Altimmune's stock has soared 969.9% over the past 12 months, while the broader S&P 500 SPX is up 21.7%.

 

Qaigen Inovio

PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.)

 

Eric Feldman

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 23, 2021-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development.

“Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders, and in the past two years, has established himself as a leader in our management group as well as in the trenches with our clinical operations team. Having spent his career dedicated to patients with hematologic malignancies, he is especially well positioned to lead our uproleselan program as it advances through Phase 3 clinical trials. In addition, his extensive clinical research background will serve us well as we drive forward other programs in our pipeline,” said Rachel King, Chief Executive Officer.

 

NewImage

COLUMBIA, Md. (February 24, 2021)—TEDCO, Maryland’s economic engine for technology companies, announced today the appointment of Jack Miner as the chief investment officer. He begins his tenure with TEDCO on March 1, 2021.

“Jack brings many years of venture capital and leadership experience to fill this critical role at TEDCO,” said Troy LeMaile-Stovall, TEDCO’s CEO and executive director. “Leveraging his extensive knowledge of the entrepreneurial and venture capital community, we’re looking forward to the impact he will make in fostering TEDCO’s mission to better serve our entrepreneurs.” 

 

Tom Baden

Congratulations to the BHI Board-members who made the list.

  • Pete Briskman - Executive Managing Director Maryland , JLL
  • Ron Daniels - President, Johns Hopkins University
  • Dr. Jay Perman - Chancellor of the University System of Maryland
 

Biographer Robert Caro, in discussing his craft, wrote that “power reveals.” It reveals the true character of people, the nature of their endeavors, their goals and ambitions.

Welcome to The Daily Record’s inaugural Power 100 List.

We are recognizing the men and women across Maryland who are shaping our businesses, governments, nonprofits, law firms and other critical institutions. In essence, they are playing an outsize role in the culture, lifestyle, civic conversation and economic fortunes of Maryland.

 

NIHSBIR

Are you a BioHealth entrepreneur working with an academic institution on your oncology R&D?  The NCI SBIR Development Center has announced a new funding opportunity to support academic post-doc transitions to industry. This new and unique Fast-Track only award structure comprises a Phase I STTR that transitions to a Phase II SBIR. An STTR award is a collaborative award made to small businesses working closely with a university deadline to apply by 3/25.  For more information, check online:  Small Business Transition Grant | NCI: SBIR & STTR (cancer.gov)

Image: https://sbir.cancer.gov/funding/sbtg From Video

Concept rendering of George Mason University's Institute for Digital InnovAtion (IDIA) in Arlington

George Mason University President Gregory Washington on Monday announced he has formed an advisory roundtable of nearly 30 regional business executives and community leaders to focus on the university’s innovation initiative.

The President’s Innovation Advisory Council will focus on issues such as GMU’s efforts to increase the pipeline of tech workers. George Mason’s innovation initiative includes $235 million in General Assembly funding to produce approximately 30% of the 25,000 undergraduate and graduate majors as part of the state’s Tech Talent Investment Program.

Image: Concept rendering of George Mason University's Institute for Digital InnovAtion (IDIA) in Arlington

NewImage

SoPE + GW Startup Pitch Application Apply now to pitch at our March 24th Event: Pitch Perfect II: In Action!

Application is limited to SoPE members or those affiliated with George Washington University (students, staff, licensees, etc). Limited spots available. Submission does not guarantee acceptance.

Submission deadline: March 5th, 2021.

 

Daniel Sangjib Min - Times-Dispatch

Richmond-based pharmaceutical development company Phlow Corp. has formed a partnership with a nonprofit organization that will involve opening new laboratory operations in downtown Richmond.

Phlow, which is working to build the supply of medicines that face shortages in the U.S. market, said Monday that it has formed a strategic alliance with United States Pharmacopeia to develop a new laboratory operation in the Virginia Bio+Tech Research Park.

Image: Daniel Sangjib Min - Times-Dispatch

money

The National Institutes of Health (NIH) small business programs, which include the Small Business Innovation Research (SBIR) and the Small Business Technology Transfer (STTR) programs, are the largest source of early stage capital for life sciences startups in the United States.  The grant money helps startups accelerate their discoveries and put their discoveries into clinical trials.  The grants awarded are just that, a grant and not a loan; there is no requirement to pay back the money. The NIH grants $1.2 billion dollars every year in the combined SBIR and STTR programs.

 

BHI MCEDC LOGOS

Don’t miss a unique opportunity to discuss your biohealth technology innovation directly with Program Officers from NSF, various institutes at NIH (including NIA, NCI, NIDA, and NHLBI), the University of Maryland MIPS program.  Learn the latest about the current areas of focus for these funding resources, Tips and Tricks for submitting successful applications, and Additional Resources to support your early stage company.   Confirmed speakers and partnering meeting participants include:

  • Stephanie Davis, PhD - Small Business Program Coordinator, NIH National Heart Lung and Blood Institute (NHLBI)
  • Stephanie Fertig, HHS Small Business Program Lead, National Institutes of Health (NIH)
  • Armineh Ghazarian - Program Analyst, NIH National Institute of Aging
  • Colleen Gibney, SBIR Deputy Project Manager, USAMRDC
  • Henry Ahn - Program Director, National Science Foundation (NSF)
  • Todd Haim, PhD – Chief, Office of Small Business Research, NIH National Institute of Aging
  • Elena Koustova, PhD, MBA - Director, Office of Translational Initiatives and Program Innovations (OTIPI), NIDA SBIR/STTR Coordinator, NIH National Institute of Drug Abuse (NIDA) Office of Director
  • JR Meyers, SBIR Project Manager, USAMRDC
  • Victor Prikhodko – Senior Business Dev. Manager, SBIR/STTR NIH National Institute of Drug Abuse (NIDA)
  • Saroj Regmi, PhD - Health Science Administrator Office of Small Business Research, NIH National Institute of Aging
  • Andrea Renner - SBIR Deputy Project Manager, USAMRDC
  • Ben Schrag, PhD - Program Director, National Science Foundation (NSF)
  • Onur Unal, Manager, Life Sciences Projects, Maryland Industrial Partnerships (MIPS), Maryland Technology Enterprise Institute (Mtech), University of Maryland

 

Additional participants from the NIH National Cancer Institute and other resources TBA.

Click here to.. Reserve your spot (no fee) today!    

NewImage

When AstraZeneca (AZ)  announced in 2019 that it was officially retiring the MedImmune brand, questions naturally arose about whether the U.K. pharma giant would continue the legacy MedImmune support for the BioHealth Capital Region’s (BHCR) life science ecosystem. 

Since its founding in 1998, MedImmune had been an anchor life science company in the region, and starting around 2014, it was a key force behind the creation of BHCR brand, as well as the region’s collective push to be a top-three biotech cluster by 2023. 

Image: https://biobuzz.io

NewImage

Something of the dark horse in the race to get a COVID-19 vaccine out to the public, Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of NVX-CoV2373, its COVID-19 vaccine candidate, for the COVAX Facility. The vaccine will be manufactured and distributed around the world by Novavax and Serum Institute of India (SII). SII has an existing deal with Gavi.

Image: https://www.biospace.com

Cursor and Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA Engineered Cell Therapy for Frontline Cancer Cartesian

Gaithersburg, MD, Feb. 22, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma.  Based upon the company’s research and analysis, this program is understood to be the first RNA-engineered cell therapy to enter clinical development for a frontline cancer. Descartes-11 is the third product candidate to be evaluated in clinical trials resulting from Cartesian’s RNA Armory℠ engineering platform.

 

BrainScope Logo

BETHESDA, Md., Feb. 16, 2021 /PRNewswire/ -- JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play.  

 

Alexandria Logo

Most office buildings around the country have remained empty over the past year as companies quickly pivoted to working remotely to help slow the pandemic's spread. However, many office campuses owned by office real estate investment trust (REIT) Alexandria Real Estate Equities (NYSE: ARE) have been buzzing with activity during the outbreak. That's because many of its tenants have been working around the clock waging war against the virus, and they needed the company's specialized lab space to develop solutions aimed at defeating the pandemic.

 

for The Rockville-based National Foundation for Cancer Research is accepting applications through Sunday evening, February 28, from academic laboratory and early stage start-up-based promising oncology technology projects for its 2021 Salisbury Award Competition for Entrepreneurial Translational Research. In addition to increased exposure, insight from a world-class judging panel and access to NFCR’s network, cash prizes totaling $10,000 will be provided to three category winners, the first one of which who will also be introduced to the AIM-HI Accelerator Fund for consideration of investment.  Learn more and apply here: https://www.nfcr.org/salisbury-award/.

Avhana’s Noah Weiner is focused on EHR integration.

Local incubator member and digital health company Avhana Health Inc. has been acquired by Wilmington, Del.-based digital medicine products company Amalgam Rx Inc. for an undisclosed sum.

Under terms of the purchase, which was announced Jan. 13, Avhana Health will maintain its operations in Los Angeles as a stand-alone subsidiary of Amalgam. Avhana’s chief executive, Noah Weiner, will stay on as general manager of the unit.

Image: Avhana’s Noah Weiner is focused on EHR integration. 

eyedea Medical Logo

The LaunchPort™ announced today that Eyedea Medical (https://www.eyedeamedical.com/) joined the Venture Center and will make the Port Covington, Baltimore location their HQ and engineering site.

Eyedea Medical is an early-stage, ophthalmic medical device company that was spun out of the Wilmer Eye Institute and the Center for Bioengineering Innovation & Design at Johns Hopkins University. Eyedea Medical was formed by a group of ophthalmologists and biomedical engineers in 2019 to alleviate the burden of corneal blindness globally through development and commercialization of a series of devices with potential to improve outcomes and access to vision-restoring corneal procedures.

 

Novavax Logo

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.

 

NewImage

As we noted in our previous story, “Diversity in Biotech, Industry’s Next Big Challenge,” there is a deep, rich, underappreciated history of African-American innovation in the life sciences and STEM fields. 

There is still much work to be done to improve equity across the industry, however. From transdermal diabetes patches and life-saving hemorrhage control systems to advanced biomanufacturing and revolutionary diagnostic testing, this history’s lineage can be traced across the Mid-Atlantic biotech clusters well as throughout the country.   

Image: https://biobuzz.io/